对实施已故患者“溯源检测”的伦理和法律限制的考察。
An Examination of the Ethical and Legal Limits in Implementing "Traceback Testing" for Deceased Patients.
机构信息
HISTORY AND SOCIOLOGY OF SCIENCE DEPARTMENT, UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, USA.
DEPARTMENT OF TRANSLATIONAL AND APPLIED GENOMICS, CENTER FOR HEALTH RESEARCH, KAISER PERMANENTE NORTHWEST, PORTLAND, OR, USA.
出版信息
J Law Med Ethics. 2022;50(4):818-832. doi: 10.1017/jme.2023.23.
Abstract
This paper examines the legal and ethical aspects of traceback testing, a process in which patients who have been previously diagnosed with ovarian cancer are identified and offered genetic testing so that their family members can be informed of their genetic risk and can also choose to undergo testing. Specifically, this analysis examines the ethical and legal limits in implementing traceback testing in cases when the patient is deceased and can no longer consent to genetic testing.
摘要
本文探讨了回溯检测的法律和伦理方面，回溯检测是指对先前被诊断患有卵巢癌的患者进行基因检测，以便告知其家属他们的遗传风险，同时也可以选择进行检测。具体而言，本分析研究了在患者已经去世且无法再同意进行基因检测的情况下，实施回溯检测的伦理和法律限制。
相似文献
1
An Examination of the Ethical and Legal Limits in Implementing "Traceback Testing" for Deceased Patients.
J Law Med Ethics. 2022;50(4):818-832. doi: 10.1017/jme.2023.23.
2
Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
Genet Epidemiol. 2018 Feb;42(1):117-122. doi: 10.1002/gepi.22095. Epub 2017 Nov 30.
3
Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol.
J Pers Med. 2021 Nov 13;11(11):1194. doi: 10.3390/jpm11111194.
4
TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
J Clin Oncol. 2022 Jun 20;40(18):2036-2047. doi: 10.1200/JCO.21.02108. Epub 2022 Mar 9.
5
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11.
6
Retrospective genetic testing (Traceback) in women with early-onset breast cancer after revised national guidelines: a clinical implementation study.
Breast Cancer Res Treat. 2024 Jun;205(3):599-607. doi: 10.1007/s10549-024-07288-9. Epub 2024 Mar 16.
7
Feasibility and Assessment of a Cascade Traceback Screening Program (FACTS): Protocol for a Multisite Study to Implement and Assess an Ovarian Cancer Traceback Cascade Testing Program.
J Pers Med. 2021 Jun 11;11(6):543. doi: 10.3390/jpm11060543.
8
Genetic testing in women with early-onset breast cancer: a Traceback pilot study.
Breast Cancer Res Treat. 2021 Nov;190(2):307-315. doi: 10.1007/s10549-021-06351-z. Epub 2021 Sep 16.
9
Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized Trial.
Public Health Genomics. 2024;27(1):100-109. doi: 10.1159/000540466. Epub 2024 Aug 22.
10
Human-Centered Design Study to Inform Traceback Cascade Genetic Testing Programs at Three Integrated Health Systems.
Public Health Genomics. 2023;26(1):45-57. doi: 10.1159/000529852. Epub 2023 Mar 3.
本文引用的文献
1
Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
JCO Precis Oncol. 2017 Nov;1:1-12. doi: 10.1200/PO.16.00066.
2
Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol.
J Pers Med. 2021 Nov 13;11(11):1194. doi: 10.3390/jpm11111194.
3
What guidance does HIPAA offer to providers considering familial risk notification and cascade genetic testing?
J Law Biosci. 2020 Dec 11;7(1):lsaa071. doi: 10.1093/jlb/lsaa071. eCollection 2020 Jan-Dec.
4
In Defence of informed consent for health record research - why arguments from 'easy rescue', 'no harm' and 'consent bias' fail.
BMC Med Ethics. 2020 Aug 20;21(1):75. doi: 10.1186/s12910-020-00519-w.
5
Return of Individual Research Results: A Guide for Biomedical Researchers Utilizing Human Biospecimens.
Am J Pathol. 2020 May;190(5):918-933. doi: 10.1016/j.ajpath.2020.01.014. Epub 2020 Mar 19.
6
How to inform at-risk relatives? Attitudes of 1379 Dutch patients, relatives, and members of the general population.
J Genet Couns. 2020 Oct;29(5):786-799. doi: 10.1002/jgc4.1206. Epub 2019 Dec 30.
7
Cancer overdiagnosis: a biological challenge and clinical dilemma.
Nat Rev Cancer. 2019 Jun;19(6):349-358. doi: 10.1038/s41568-019-0142-8.
8
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
J Clin Oncol. 2019 May 20;37(15):1305-1315. doi: 10.1200/JCO.18.01854. Epub 2019 Apr 9.
9
"It would be so much easier": health system-led genetic risk notification-feasibility and acceptability of cascade screening in an integrated system.
J Community Genet. 2019 Oct;10(4):461-470. doi: 10.1007/s12687-019-00412-z. Epub 2019 Mar 6.
10
Returning Results to Family Members: Professional Duties in Genomics Research in the United States.
J Leg Med. 2018 Apr-Jun;38(2):201-219. doi: 10.1080/01947648.2017.1417934.
Zotero 插件